| Autor: |
Hsing V; Translational Medicine Program, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada., Zhao HQ; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.; Centre for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada.; Centre for Innovation, Canadian Blood Services, Vancouver, British Columbia, Canada., Post M; Translational Medicine Program, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada.; Department of Physiology, University of Toronto, Toronto, Ontario, Canada., Devine D; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.; Centre for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada.; Centre for Innovation, Canadian Blood Services, Vancouver, British Columbia, Canada., McVey MJ; Translational Medicine Program, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada.; Department of Physiology, University of Toronto, Toronto, Ontario, Canada.; Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada.; Department of Physics, Toronto Metropolitan University, Toronto, Ontario, Canada. |
| Abstrakt: |
Cold-stored (CS) platelets are once again being reintroduced for clinical use. Transfused CS platelets offer benefits over room temperature-stored (RTS) platelets such as increased hemostatic effects and prolongation of shelf-life. Despite these advantages little is known about their association with transfusion-related acute lung injury (TRALI). TRALI is associated with prolonged storage of RTS platelets and has a mortality of >15%. Determining the safety of CS platelets is important considering their proposed use in TRALI-vulnerable populations with inflammation such as surgical patients or patients with trauma. Donor platelet-derived ceramide causes TRALI, whereas donor platelet sphingosine-1-phosphate (S1P) is barrier protective. Females have higher plasma levels of S1P than males. Cold temperatures increase S1P levels in cells. Therefore, we hypothesized that female (donors or recipients) and/or CS platelets would decrease TRALI. To test this, we compared how male and female donor and recipient allogeneic platelet transfusions of CS (4°C) versus RTS (23°C) platelets stored for 5 days influence murine TRALI. Transfusion of CS platelets significantly reduced recipient lung tissue wet-to-dry ratios, bronchoalveolar lavage total protein, lung tissue myeloperoxidase enzyme activity, histological lung injury scores, and increased plasma sphingosine-1-phosphate (S1P) levels compared with RTS platelet transfusions. Female as opposed to male recipients had less TRALI and higher plasma S1P levels. Female donor mouse platelets had higher S1P levels than males. Mouse and human CS platelets had increased S1P levels compared with RTS platelets. Higher recipient plasma S1P levels appear protective considering females, and males receiving platelets from females or male CS platelets had less TRALI. NEW & NOTEWORTHY Transfusion-related acute lung injury (TRALI) though relatively rare represents a severe lung injury. The sphingolipid sphingosine-1-phosphate (S1P) regulates the severity of platelet-mediated TRALI. Female platelet transfusion recipient plasmas or stored platelets from female donors have higher S1P levels than males, which reduces TRALI. Cold storage of murine platelets preserves platelet-S1P, which reduces TRALI in platelet-transfused recipients. |
